Philippe Wiesel, Md
Executive Vice President and Chief Medical Officer
Management
genkyotex
Switzerland
Biography
Philippe joined Genkyotex in 2010 and is responsible for all clinical development activities. Previously, Philippe founded Genexion, a clinical development company focused on developing early stage clinical assets with emerging biotech companies and European venture capital firms. Prior to founding Genexion, Philippe was Medical Director at Serono's Swiss and US offices, where he was involved with the global development of several biologics and small molecules. In particular, he led the late-stage clinical development of Raptiva, achieving the first marketing authorization in Europe for a biological therapy targeting psoriasis. Philippe also led the development of Onercept in psoriasis and managed clinical development programs for beta interferon, interleukin-18 binding protein, and atacicept. Prior to joining the biotech industry, he conducted basic research for over five years in the laboratories of Professor Edgar Haber at Harvard Medical School, and Professor Hans Brunner at the Division of Hypertension in Lausanne. Philippe holds a MD degree from the University of Lausanne.
Research Interest
clinical development activities.
